-
How engineered tissues, gene-edited cells, and immune-modulating signals work together to drive functional regeneration
-
The scientific, manufacturing, and regulatory challenges of translating complex, biology-driven therapies into clinical practice
-
What founders, clinicians, and investors need to understand about building scalable, durable regenerative healthcare solutions
Shayn Peirce-Cottler – Session Moderator Professor and Chair, Biomedical Engineering University of Virginia
Stephen Kennedy Head of Technical Operations CRISPR Therapeutics
Prakash Kolli CEO and Co-Founder 3D Orthobiologic SolutionsDon Griffin Chief Scientific Officer Tempo Therapeutics